Status:
COMPLETED
Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression
Lead Sponsor:
Rennes University Hospital
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The myeloma microenvironment is the target of many drugs in development, and it is unclear how they can be combined with reference treatments such as lenalidomide. This pilot study consists of an exte...
Detailed Description
With the significant increase in the number of therapeutic combinations targeting the tumour microenvironment, it is crucial to better understand the effect of reference myeloma treatments on the diff...
Eligibility Criteria
Inclusion
- Patient with newly diagnosed multiple myeloma;
- Patient not eligible for intensive treatment;
- Patient for whom first-line treatment with Lenalidomide-Dexamethasone will be initiated;
- Patient accepting the performance of an additional myelogram at the end of the 1st treatment cycle.
- Patient aged 18 years or older;
- Patient who has given free, informed and written consent;
- Patient affiliated to a social security scheme
- For women of childbearing age, use of effective contraception
Exclusion
- Patient with relapsed multiple myeloma;
- Patient eligible for intensive treatment;
- Patient for whom chemotherapy involves treatment other than Lenalidomide-Dexamethasone;
- Patient with a contraindication to lenalidomide treatment
- Pregnant or breastfeeding woman;
- Person subject to legal protection (safeguard of justice, curatorship,guardianship) or person deprived of liberty.
Key Trial Info
Start Date :
July 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 27 2023
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04872023
Start Date
July 29 2021
End Date
January 27 2023
Last Update
February 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Rennes
Rennes, France